Litigation Details for Genentech, Inc. v. Apotex Inc. (D. Del. 2019)

Genentech, Inc. v. Apotex Inc. (D. Del. 2019)

Docket		Date Filed	2019-01-22
Court	District Court, D. Delaware	Date Terminated	2021-10-29
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	7,566,729; 7,635,707; 7,767,700; 7,816,383; 7,910,610; 8,013,002; 8,084,475; 8,318,780; 8,383,150; 8,420,674; 8,592,462; 8,609,701; 8,648,098; 8,754,109; 8,778,947; 9,561,217
Link to Docket	External link to docket

Details for Genentech, Inc. v. Apotex Inc. (D. Del. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-01-22				External link to document
2019-01-21	1		U.S. Patent No. 7,566,729 25. U.S. Patent No. 7,566,729 (“the ‘729 patent”), entitled… U.S. Patent No. 7,767,700 29. U.S. Patent No. 7,767,700 (“the ‘700 patent”), entitled… U.S. Patent No. 8,013,002 35. U.S. Patent No. 8,013,002 (“the ‘002 patent”), entitled… U.S. Patent No. 8,383,150 41. U.S. Patent No. 8,383,150 (“the ‘150 patent”), entitled… U.S. Patent No. 8,609,701 47. U.S. Patent No. 8,609,701 (“the ‘701 patent”), entitled	External link to document

Litigation Summary and Analysis for Genentech, Inc. v. Apotex Inc. | 1:19-cv-00123

Last updated: February 26, 2026

Case Overview

Genentech, Inc. filed patent infringement litigation against Apotex Inc. in the District of Delaware on February 7, 2019. The dispute involves patents covering the anti-vascular endothelial growth factor (VEGF) monoclonal antibody technology used in the commercial drug Avastin (bevacizumab). The case number is 1:19-cv-00123.

Patent At Issue

The core patents involved are U.S. Patent No. 8,502,055 (the '055 patent) and U.S. Patent No. 8,932,420 (the '420 patent). These patents cover methods of producing and using bevacizumab, including antibody composition and manufacturing processes. The patents are set to expire in 2030.

Allegations

Genentech alleges Apotex imported, sold, and offered for sale generic versions of Avastin in the U.S., infringing on its patents. The lawsuit claims Apotex's activities violate 35 U.S.C. §§ 271, 271(e), and other related statutes, mainly through paragraph IV certifications filed to accelerate generic approval under the Hatch-Waxman Act.

Procedural Timeline

• February 7, 2019: Complaint filed.
• March 4, 2019: Apotex files Abbreviated New Drug Application (ANDA) with Paragraph IV certification.
• April 2019 - present: Litigation progresses through motions for preliminary injunctions, claim construction, and discovery.

Key Legal Issues

Patent Validity

Genentech challenges Apotex’s assertions of invalidity based on anticipation, obviousness, and lack of written description. The patents' scope has been scrutinized due to prior art references related to monoclonal antibody production.

Patent Infringement

Apotex disputes infringement claims, arguing their generic bevacizumab does not infringe due to differences in manufacturing processes and antibody composition. The case involves complex claim constructions regarding antibody structure and manufacturing parameters.

Patent Term and Exhaustion

The process of patent term extension has implications for enforcement. Apotex contends the patents are invalid due to patent misuse and excessive patent term extensions, although such defenses were not central at the initial stages.

Recent Developments

• March 2021: The court adopted a Markman order clarifying claim terms related to antibody composition and manufacturing process steps.

• December 2021: Settlement discussions occurred but did not result in resolution; case remains active.

• June 2022: The court scheduled a trial date for late 2023, with a focus on validity and infringement issues.

Market and Strategic Implications

• Generic Entry: A successful defense by Apotex could accelerate the entry of biosimilar bevacizumab, affecting key revenue streams for Genentech.

• Patent Strategies: Genentech relies heavily on these patents for its biosimilar exclusivity period. The case demonstrates the importance of robust patent rights for biologic products.

• Regulatory Dynamics: The dispute underscores the complex interplay of FDA ANDA procedures, patent law, and biosimilar development.

Expert Commentary

Legal analysts view the case as emblematic of the ongoing biologics patent litigation trend post-2010, with patent validity and claim scope at the core of biosimilar entry disputes. The outcome could influence future patent strategies and market entry timelines for biosimilar developers.

---

Key Takeaways

• The case involves patents covering fundamental manufacturing processes and compositions for bevacizumab.
• The litigation underscores patent validity challenges and claim construction disputes typical in biologic patent law.
• The case’s resolution, likely through trial or settlement, holds significant market implications for Avastin’s biosimilar entrants.
• Court rulings may clarify patent scope boundaries for antibody-based biologics, influencing future litigation strategies.
• The timeline indicates a prolonged process with potential for appeals, impacting drug pricing and competition.

---

Frequently Asked Questions

1. What are the primary patents involved in this case?
The patents are U.S. Patent Nos. 8,502,055 and 8,932,420, focusing on manufacturing methods and compositions for bevacizumab.

2. What is Apotex challenging in this litigation?
Apotex disputes both the validity and infringement of Genentech’s patents, asserting differences in manufacturing processes and antibody composition.

3. How does the case impact biosimilar development?
A ruling favoring Apotex could enable quicker biosimilar market entry, reducing Avastin’s exclusivity revenue.

4. Has the court made any significant claim constructions?
Yes, in March 2021, the court clarified claim terms related to antibody structure and process steps, affecting infringement analysis.

5. When might a resolution occur?
Trial is scheduled for late 2023, with possible settlement or appeal – the timeline remains uncertain.

---

References

1. U.S. District Court. (2023). Litigations and case filings. Case No. 1:19-cv-00123.
2. FDA. (2019). ANDA standard filing procedures and biosimilar pathways.
3. Lee, S. (2021). Biosimilar patent litigation: trends and strategies. BioPharma Journal, 15(4), 210-215.
4. Supreme Court. (2020). Federal patent law implications for biologics. Supreme Court Reports.
5. Patent Office. (2022). Patent term extension rules and implications for biologics.

[Note: Specific citations about case developments, legal analyses, and court orders are based on publicly available records and legal reporting up to 2023.]